Glorifin Belmonte
Psychiatry · Honolulu, HINPI 1447346150
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 281 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$975
- AbbVie$817
- Sunovion Pharmaceuticals Inc.$655
- Teva Pharmaceuticals USA, Inc.$575
- Otsuka America Pharmaceutical, Inc.$477
- Neurocrine Biosciences, Inc.$457
- plus $2K from 8 others
What the payments were for
- Food & beverage$5,31297%
- Education$1663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 57 | $975 |
| AbbVie(2 entities) | 44 | $817 |
| Sunovion Pharmaceuticals Inc. | 37 | $655 |
| Teva Pharmaceuticals USA, Inc. | 25 | $575 |
| Otsuka America Pharmaceutical, Inc. | 26 | $477 |
| Neurocrine Biosciences, Inc. | 20 | $457 |
| Johnson & Johnson | 18 | $388 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $365 |
| Lundbeck LLC | 19 | $322 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $290 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Insmed, Inc. | 1 | $50 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $22 |
How this compares
$5,478 in reported general payments places this provider in the 90th percentile of 183 psychiatry providers in Hawaii.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 59 | $213,525 |
| IngrezzaValbenazine Tosylate | 19 | $167,430 |
| AristadaAripiprazole Lauroxil | 45 | $113,968 |
| AustedoDeutetrabenazine | 12 | $101,941 |
| Abilify MaintenaAripiprazole | 31 | $92,503 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $29,188 |
| Lurasidone Hcl | 75 | $25,718 |
| Aripiprazole | 96 | $21,935 |
| Paliperidone ErPaliperidone | 34 | $21,036 |
| TrintellixVortioxetine Hydrobromide | 16 | $16,950 |
| Risperidone OdtRisperidone | 31 | $6,404 |
| Olanzapine | 128 | $4,950 |
| Quetiapine Fumarate | 135 | $4,003 |
| Risperidone | 103 | $2,728 |
| Clozapine | 57 | $2,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $388 | $213,52559 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $457 | $167,43019 claims |
| Alkermes, Inc.Aristada, Lybalvi | $975 | $143,15661 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $575 | $101,94112 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $477 | $92,50331 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $290 | $16,95016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 183 psychiatry providers in Hawaii.
Other psychiatry in Honolulu
- Denis Mee-LeeHonolulu$526K
- David SteinHonolulu$186K
- Gregory YuenHonolulu$6K
- Raymond DavidsonHonolulu$6K
- Helen Blaisdell-BrennanHonolulu$6K
- Brett LuHonolulu$5K
- Donna McBrien SliwowskiHonolulu$4K
- Alan BuffensteinHonolulu$3K
- Nancy LuckieHonolulu$3K
- Angela KingHonolulu$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.